Cerebrolysin to prevent intracranial bleeding after intravenous thrombolysis (blood clot) in patients with ischemic stroke

Phase 3

Completed

• Conditions: Ischemic stroke; Circulatory System

• Registration Number: ISRCTN87656744
• Lead Sponsor: State Autonomous Institution of Health Interregional Clinical Diagnostic Center

Brief Summary

2023 Results article in https://pubmed.ncbi.nlm.nih.gov/36973684/ results (added 28/03/2023) 2021 Abstract results in https://doi.org/10.1177/23969873211034932 Results abstract European Stroke Organisation Conference 2021 (added 29/03/2023) 2023 Results article in https://doi.org/10.17116/jnevro202312308260 (added 11/09/2023) 2024 Other publications in https://doi.org/10.3389/fphar.2023.1288718 Post hoc analysis (added 22/01/2024) 2023 Abstract results in https://doi.org/10.1159/000534859 (added 23/01/2024) 2024 Other publications in https://pubmed.ncbi.nlm.nih.gov/38512096/ Post hoc analysis (added 02/04/2024)

Detailed Description

Not available

Study Timeline

• Study Completion: 2020-11-30
• Study Start: 2021-02-16
• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 341

Inclusion Criteria

1. Patients with confirmed diagnosis of acute ischemic stroke (AIS)
2. Male or female gender
3. Age =18 years
4. Admission to one of the sites within 4.5 h after the AIS onset
5. Indications for intravenous thrombolytic therapy

Exclusion Criteria

1. Contraindications for intravenous thrombolytic therapy
2. Contraindications for Cerebrolysin
3. Signs of hemorrhagic transformation or intracranial hemorrhage on the screening CT scan
4. Any other concurrent life-threatening medical condition

Study & Design

• Study Type: Interventional
• Study Design: Not specified